Ambre Bender

Ambre Bender

Auto-generated profile, based on publicly available information

Ambre Bender

CNRS, University of Strasbourg, UMR 7242 Biotechnology and Cell Signaling, 300 Bd Sébastien Brant, Illkirch, 67412, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
TDThomas Dahlet
Thomas Dahlet
ALAndrea Argüeso Lleida
Andrea Argüeso Lleida
HAHala Al Adhami
Hala Al Adhami
MDMichael Dumas
Michael Dumas
ABAmbre Bender
Ambre Bender
MWMichael Weber
Michael Weber
Mouse embryos acquire global DNA methylation of their genome during implantation. However the exact roles of DNA methyltransferases (DNMTs) in embryos have not been studied comprehensively. Here we systematically analyze the consequences of genetic inactivation of Dnmt1, Dnmt3a and Dnmt3b on the methylome and transcriptome of mouse embryos. We find a strict division of function between DNMT1, responsible for maintenance methylation, and DNMT3A/B, solely responsible for methylation acquisition in development. By analyzing severely hypomethylated embryos, we uncover multiple functions of DNA methylation that is used as a mechanism of repression for a panel of genes including not only imprinted and germline genes, but also lineage-committed genes and 2-cell genes. DNA methylation also suppresses multiple retrotransposons and illegitimate transcripts from cryptic promoters in transposons and gene bodies. Our work provides a thorough analysis of the roles of DNA methyltransferases and the importance of DNA methylation for transcriptome integrity in mammalian embryos.

1 January 2014 in Genome Biology
Verified
Journal Article
Open access
PDF file
GAGhislain Auclair
Ghislain Auclair
SGSylvain Guibert
Sylvain Guibert
ABAmbre Bender
Ambre Bender
MWMichael Weber
Michael Weber
In the mouse, the patterns of DNA methylation are established during early embryonic development in the epiblast. We quantified the targets and kinetics of DNA methylation acquisition in epiblast cells, and determined the contribution of the de novo methyltransferases DNMT3A and DNMT3B to this process. We generated single-base maps of DNA methylation from the blastocyst to post-implantation stages and in embryos lacking DNMT3A or DNMT3B activity. DNA methylation is established within two days of implantation between embryonic days 4.5 and 6.5. The kinetics of de novo methylation are uniform throughout the genome, suggesting a random mechanism of deposition. In contrast, many CpG islands acquire methylation slowly in late epiblast cells. Five percent of CpG islands gain methylation and are found in the promoters of germline genes and in exons of important developmental genes. The onset of global methylation correlates with the upregulation of Dnmt3a/b genes in the early epiblast. DNMT3A and DNMT3B act redundantly to methylate the bulk genome and repetitive elements, whereas DNMT3B has a prominent role in the methylation of CpG islands on autosomes and the X chromosome. Reduced CpG island methylation in Dnmt3b-deficient embryos correlates with gene reactivation in promoters but reduced transcript abundance in gene bodies. Finally, DNMT3B establishes secondary methylation marks at imprinted loci, which distinguishes bona fide germline from somatic methylation imprints. We reveal that the DNMT3 de novo methyltransferases play both redundant and specific functions in the establishment of DNA methylation in the mouse embryo.

9 August 2025 in Nature Communications
Verified
Journal Article
Open access
ABAmbre Bender
Ambre Bender
MMMarion Morel
Marion Morel
MDMichael Dumas
Michael Dumas
MKMuriel Klopfenstein
Muriel Klopfenstein
NONaël Osmani
Naël Osmani
MWMichael Weber
Michael Weber
In mammals, primordial germ cells (PGCs) undergo global erasure of DNA methylation with delayed demethylation of germline genes and selective retention of DNA methylation at evolutionarily young retrotransposons. However, the molecular mechanisms of persistent DNA methylation in PGCs remain unclear. Here we report that resistance to DNA methylation reprogramming in PGCs requires UHRF2, the paralog of the DNMT1 cofactor UHRF1. PGCs from Uhrf2 knock-out mice show loss of retrotransposon DNA methylation, while DNA methylation is unaffected in somatic cells. This is not associated with changes in the expression of retrotransposons in E13.5 PGCs, indicating that other mechanisms compensate for retrotransposon control at this stage. Furthermore, Uhrf2-deficient PGCs show precocious demethylation of germline genes and overexpress meiotic genes in females. Subsequently, Uhrf2-deficient mice show impaired oocyte development and female-specific reduced fertility, as well as incomplete remethylation of retrotransposons during spermatogenesis. These findings reveal a crucial function for the UHRF1 paralog UHRF2 in controlling DNA methylation in the germline.

16 May 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
CFClaire Fonti
Claire Fonti
ASAnne Saumet
Anne Saumet
AAAmanda Abi‐Khalil
Amanda Abi‐Khalil
BOBéatrice Orsetti
Béatrice Orsetti
ECElouan Cleroux
Elouan Cleroux
Charles TheilletCharles Theillet
Charles Theillet

11 June 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
CFClaire Fonti
Claire Fonti
ASAnne Saumet
Anne Saumet
AAAmanda Abi-Khalil
Amanda Abi-Khalil
BOBéatrice Orsetti
Béatrice Orsetti
William JacotWilliam Jacot
William Jacot
Charles TheilletCharles Theillet
Charles Theillet
Gene expression differences, combined with distinct patterns of genomic rearrangements and epigenetic modifications, have laid the bases of molecular classification of breast cancer. Different molecular subtypes are thought to originate from different cell lineages in the mammary gland, but the early activation of an oncogene could also play a role. It is, however, difficult to discriminate the respective inputs of oncogene activation or cell type of origin in the natural history of the tumor. In this work, we have designed an experimental strategy aiming at determining whether activation of distinct oncogenic pathways in human mammary epithelial cells (HMEC) could lead to different patterns of genetic and epigenetic changes. We show that initial activation of CCNE1, WNT1 and RASv12, which activate distinct oncogenic pathways, in shp53 immortalized HMECs results in different and reproducible profiles of mRNA and miRNA expression, copy number alterations (CNA) and DNA methylation modifications. Noticeably, HMECs transformed by RAS bore very specific profiles of CNAs and DNA methylation, clearly distinct from those shown by CCNE1 and WNT1 transformed HMECs. Genes impacted by CNAs and CpG methylation in the RAS and the CCNE1/WNT1 clusters showed clear differences, illustrating the activation of distinct pathways. Our data show that early activation of distinct oncogenic pathways leads to active adaptive events resulting in specific sets of CNAs and DNA methylation changes. We, thus, propose that activation of different oncogenes could have a role in reshaping the genetic landscape of breast cancer subtypes. Author summary: Genetic and epigenetic changes are at the center of cancer development. Breast cancer molecular subtypes are defined on differences in genetic and epigenetic profiles and it is generally assumed these subtypes originate from different cell lineages in the mammary gland. We propose that founding oncogenic mutations could also have an impact. To address this question, we designed an experimental model, based on the ectopic expression of different oncogenes in human mammary epithelial cells (HMEC), and monitored genetic and DNA methylation changes occurring at different stages of cell transformation. We show that transformation of HMEC by distinct oncogenes resulted in clearly different and reproducible patterns of genetic and DNA methylation changes. Genes whose expression was modified by either CNAs or CpG methylation were consistent with the dominant pathways activated and reflected the phenotypes in the respective models. We propose that DNA methylation and CNA changes correspond to adaptive responses to the activation of the oncogenic pathways. Our data strongly suggest that early activation of distinct oncogenic insults will not only impinge on the phenotypic characteristics of the resulting tumors, but also have a strong impact on their genomic and epigenetic landscapes.

2 April 2026
Verified
Thesis
Closed access
ABAmbre Bender-Osmani
Ambre Bender-Osmani
La méthylation de l’ADN est la marque épigénétique la plus connue. Elle consiste en l’ajout d’un groupement méthyle au niveau de la cytosine, produisant la 5-méthyl-cystosine (5mC). Cette réaction chimique est catalysée par des ADN méthyltransférases : DNMT1, DNMT3A et DNMT3B. Peu de choses sont connues concernant les changements de 5mC au cours des lignages cellulaires dans l’embryon et comment cette marque contribue à l’établissement ou au maintien de l’identité cellulaire. Nous avons cherché à mieux comprendre ces mécanismes en étudiant la 5mC dans deux lignages cellulaires : les cellules primordiales germinales (PGCs) et les cellules souches hématopoïétiques (HSCs). Nous avons généré les premiers méthylomes de ces cellules au cours de leur développement chez la souris. Chez les PGCs, nous avons mis en évidence l’existence de deux phases de reprogrammation de la 5mC. Une première phase entre E9,5 et E13,5, où le génome des PGCs se déméthyle et une phase de reméthylation entre E14,5 et E17,5, chez les gamètes mâles uniquement. Néanmoins, certaines régions, dont notamment les éléments transposables sont résistants à la vague de déméthylation. L’utilisation de souris conditionnellement, nous a permis de mettre en évidence l’implication des protéines DNMT1 et UHRF2 dans le maintien de la 5mC au niveau de ces séquences. Concernant les HSCs, nous avons mis en évidence qu’elles acquièrent un profil de 5mC qui leur est propre lors de deux phases. La première a lieu dès l’apparition des HSCs dans l’organisme tandis que l’acquisition de la signature hématopoïétique définitive se déroule à l’âge adulte dans la moelle osseuse. L’utilisation de souris conditionnelles, nous a permis de mettre en exergue l’implication de DNMT3A et DNMT3B dans la mise en place de ces profils, avec un rôle prépondérant de DNMT3B lors de la phase d’acquisition précoce et de DNMT3A lors du verrouillage de leur profil de 5mC.